Literature DB >> 35830884

NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022.

Douglas E Wood1, Ella A Kazerooni2, Denise Aberle3, Abigail Berman4, Lisa M Brown5, Georgie A Eapen6, David S Ettinger7, J Scott Ferguson8, Lifang Hou9, Dipen Kadaria10, Donald Klippenstein11, Rohit Kumar12, Rudy P Lackner13, Lorriana E Leard14, Inga T Lennes15, Ann N C Leung16, Peter Mazzone17, Robert E Merritt18, David E Midthun19, Mark Onaitis1, Sudhakar Pipavath11, Christie Pratt20, Varun Puri21, Dan Raz22, Chakravarthy Reddy23, Mary E Reid24, Kim L Sandler25, Jacob Sands26, Matthew B Schabath11, Jamie L Studts27, Lynn Tanoue28, Betty C Tong29, William D Travis30, Benjamin Wei31, Kenneth Westover32, Stephen C Yang7, Beth McCullough33, Miranda Hughes33.   

Abstract

The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting individuals for screening and provide recommendations for evaluation and follow-up of lung nodules found during initial and subsequent screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.

Entities:  

Mesh:

Year:  2022        PMID: 35830884     DOI: 10.6004/jnccn.2022.0036

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   12.693


  3 in total

1.  Early Diagnosis of Lung Cancer: The Urgent Need of a Clinical Test.

Authors:  Roberto Gasparri; Alessandra Guaglio; Lorenzo Spaggiari
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

Review 2.  Emerging Approaches to Complement Low-Dose Computerized Tomography for Lung Cancer Screening: A Narrative Review.

Authors:  Bradley Maller; Tawee Tanvetyanon
Journal:  Cureus       Date:  2022-07-26

3.  The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials.

Authors:  Bi-Cheng Wang; Wen-Xuan Zhang; Bo-Hua Kuang; Guo-He Lin
Journal:  PLoS One       Date:  2022-10-10       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.